Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28586196 | 0.86 | SMN1; SMN2 (0.65) | SMN1; SMN2PTPN1MAPK1TSHRL3MBTL1 | |
| SCHEMBL30350539 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL4156068 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL3671710 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2PTPN1MAPK1TSHRL3MBTL1 | |
| SCHEMBL7942502 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2PTPN1MAPK1TSHRL3MBTL1 | |
| SCHEMBL7567008 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2PTPN1MAPK1TSHRL3MBTL1 | |
| SCHEMBL3713210 | 0.77 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPK1TSHRL3MBTL1POLB | |
| SCHEMBL26586940 | 0.77 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPK1TSHRL3MBTL1POLB | |
| SCHEMBL2046409 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2PTPN1MAPK1TSHRL3MBTL1 | |
| SCHEMBL29403193 | 0.76 | APP (0.39) | SMN1; SMN2PTPN1TSHRL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505739-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505739-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505739-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8865701-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865701-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865701-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| EP-2398789-B1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2398789-B1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2398789-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| WO-2010094242-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010094242-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | SMN1; SMN2 2299/4885PTPN1 3646/4885MAPK1 2490/4885 |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | SMN1; SMN2 2299/4885PTPN1 3646/4885MAPK1 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.